Targeting a specific protein to improve treatment for chondrosarcoma
ASPH Targeted Therapy for Chondrosarcoma
This study is looking for better ways to help people with chondrosarcoma, a tough bone cancer, by testing new treatments that target a specific protein linked to tumor growth, and patients may have the chance to participate in these exciting trials.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Rhode Island Hospital NIH-funded |
| Lab location | 1 site (Providence, United States) |
| Project ID | NIH-10993100 on NIH RePORTER |
What this research studies
This research aims to enhance the survival and quality of life for patients with chondrosarcoma, a challenging bone cancer with limited treatment options. The approach focuses on targeting aspartate β-hydroxylase (ASPH), a protein that is re-expressed in chondrosarcoma and is linked to tumor growth and metastasis. By investigating new treatment strategies that inhibit ASPH and its associated pathways, the research seeks to develop more effective therapies beyond the current reliance on surgery. Patients may be involved in trials assessing these innovative treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with chondrosarcoma who have limited treatment options.
Not a fit: Patients with other types of cancer or those who do not have chondrosarcoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective therapies for chondrosarcoma, significantly improving patient outcomes.
How similar studies have performed: While targeting ASPH is a novel approach in chondrosarcoma treatment, similar strategies have shown promise in other cancers, indicating potential for success.
Where this research is happening
Providence, United States
- Rhode Island Hospital — Providence, United States (Active)
Researchers
- Principal investigator: Terek, Richard M — Rhode Island Hospital
- Study coordinator: Terek, Richard M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.